Skip to main
PLRX

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics is well-positioned for future success, with its strong scientific understanding of integrin biology and a highly experienced management team that has successfully navigated the regulatory landscape. Despite early stage clinical pipeline, the company's meticulously designed trials and promising data from its lead program provide evidence of a potentially successful commercial product in the making. Additionally, PLNRX's management team, with a proven track record of drug launches, further mitigates the potential commercial risk for the company.

Bears say

Pliant Therapeutics is positioned to unlock significant value through its novel integrin-targeting delivery platform that has the potential to target specific tissue types based on cell-specific integrin receptors. With a focus on siRNA delivery, the company's programs have the potential for broad applications across multiple disease areas. This innovative platform is a key value driver for Pliant Therapeutics and could lead to future success.

PLRX has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Hold based on their latest research and market trends.

According to 3 analysts, PLRX has a Hold consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.